Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

BACKGROUND: Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low immunity and high levels of comorbidities, we investigate how targeted use of nirmatrelvir/ritonavir (brand...

Descripción completa

Detalles Bibliográficos
Autores principales: Brault, Antoine, Tran-Kiem, Cécile, Couteaux, Clément, Olié, Valérie, Paireau, Juliette, Yazdanpanah, Yazdan, Ghosn, Jade, Martin-Blondel, Guillaume, Bosetti, Paolo, Cauchemez, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672948/
https://www.ncbi.nlm.nih.gov/pubmed/36406383
http://dx.doi.org/10.1016/j.lanwpc.2022.100634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672948/
https://www.ncbi.nlm.nih.gov/pubmed/36406383
http://dx.doi.org/10.1016/j.lanwpc.2022.100634

Ejemplares similares